Since PSMA-targeted therapy demonstrated therapeutic efficacy in prostate cancer patients, maybe this treatment could also provide beneficial effects in other cancers characterized by PSMA overexpression (in tumor cells or in the neovasculature) [28]. This evidence concerns the gene FOLH1 and neoplasm.